亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 甲磺酸雷沙吉蘭 CAS號: 161735-79-1
甲磺酸雷沙吉蘭 CAS號: 161735-79-1
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 161735-79-1
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息
甲磺酸雷沙吉蘭
CAS號: 161735-79-1
中文同義詞: (R)-N-2-丙炔基-1-氫化茚胺甲磺酸鹽;甲磺酸雷沙吉蘭;雷沙吉蘭甲磺酸鹽
英文名稱: Rasagiline mesylate
英文同義詞: RASAGILINE MESYLATE;(r)-n-2-propynyl-1-indanamine methanesulfonate;(1R)-2,3-Dihydro-N-2-propyn-1-yl-1H-inden-1-amine Mesylate;(R)-N-2-Propynyl-1-indanamine Mesylate;Agilect;Azilect;TVP-101;Rasagiline nesylate
分子式: C13H17NO3S
分子量: 267.34398
含量:≥99.0%
標準:企業標準
性狀:類白色至白色結晶性粉末
用途:帕金森病(pd)早期治療的一線用藥
包裝:可根據客戶要求包裝
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31570  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |